Form 4: Inozyme Pharma COO Matthew Winton Acquires Shares Through Employee Stock Purchase Plan

Inozyme Pharma, Inc.'s Chief Operating Officer, Matthew Winton, acquired 14,355 shares of common stock at $0.74 per share through the company's Employee Stock Purchase Plan.

Summary

• Matthew Winton, Chief Operating Officer (COO) of Inozyme Pharma, Inc. (INZY), acquired 14,355 shares of the company's common stock.
• The transaction occurred on June 25, 2025.
• The shares were purchased at a price of $0.74 per share.
• This acquisition was made under the Inozyme Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP).
• The purchase price of $0.74 represents 85% of the closing price of the Issuer's common stock on April 1, 2025, which was the first trading day of the ESPP purchase period (April 1, 2025, to June 25, 2025).
• Following this transaction, Matthew Winton beneficially owns 21,743 shares of Inozyme Pharma, Inc. common stock directly.

Sentiment

Score: 7

Explanation: The acquisition of shares by a key executive, even through an ESPP, is generally a positive signal, indicating confidence in the company's future. It aligns management's interests with shareholders.

Positives

• The acquisition of shares by a key executive like the COO indicates confidence in the company's future prospects.
• Participation in the Employee Stock Purchase Plan (ESPP) demonstrates alignment of executive interests with shareholder interests.
• The purchase at a discounted price ($0.74, which is 85% of the April 1, 2025 closing price) is a standard benefit of an ESPP, making it an attractive way for employees to build equity.

Future Outlook

NA

Industry Context

Employee Stock Purchase Plans (ESPPs) are common compensation and retention tools across various industries, including the pharmaceutical and biotechnology sectors. They encourage employee ownership and align employee interests with company performance. This specific transaction reflects a routine participation in such a plan by a key executive within the biotech industry.

Comparison to Industry Standards

• Participation in an Employee Stock Purchase Plan (ESPP) by executives is a standard practice across publicly traded companies, including those in the biotechnology sector like Inozyme Pharma, Inc.
• The discount offered (85% of the closing price on the first day of the purchase period) is a common feature of ESPPs, designed to incentivize employee participation.
• While this specific transaction doesn't compare to company-wide financial results or project milestones, it aligns with typical corporate governance practices that encourage insider ownership.

Corporate Governance

Related Party Transactions

• The purchase of shares by an executive (Matthew Winton) from the company (Inozyme Pharma, Inc.) through an Employee Stock Purchase Plan (ESPP) is a related party transaction.

Stakeholder Impact

• Shareholders: The transaction may be viewed positively as it indicates insider confidence and aligns executive interests with shareholder value.
• Employees: The ESPP provides an opportunity for employees, including executives, to acquire company stock at a discount, fostering a sense of ownership and potentially increasing employee retention.

Key Dates

Recommendation

Keywords

Inozyme Pharma, INZY, Matthew Winton, COO, SEC Form 4, Insider Trading, Stock Purchase, Employee Stock Purchase Plan, ESPP, Common Stock, Beneficial Ownership